Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 150-Day, Prospective, Phase 4, Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Testosterone Nasal Gel (Natesto™)

NCT02937740 is registered in ClinicalTrials.gov with Acerus Pharmaceuticals Corporation as lead sponsor.

NCT NCT02937740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02937740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 150-Day, Prospective, Phase 4, Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Testosterone Nasal Gel (Natesto™)
Lead sponsor
Acerus Pharmaceuticals Corporation
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2016
Completion date
November 30, 2017
Enrollment
117 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hypogonadism